Institutional Investor Sells $6.67M in Shares Following Negative Clinical Trial Results
Summary
An institutional investor sold $6.67 million worth of Gossamer Bio shares, reducing its stake to 1.7%, coinciding with the company's announcement of a failed Phase 3 clinical trial.
Key Events
-
Significant Share Sale
Growth Equity Opportunities 18 VGE, LLC sold 17,093,034 shares of common stock at a weighted average price of $0.3906 per share, totaling approximately $6.67 million.
-
Reduced Ownership Stake
Following the sales, the reporting group's beneficial ownership decreased to 4,065,134 shares, representing 1.7% of the outstanding common stock.
-
Coincides with Negative Clinical Data
The sales occurred on February 23, 2026, the same day Gossamer Bio announced its Phase 3 PROSERA study for seralutinib missed its primary endpoint.
Analysis
Growth Equity Opportunities 18 VGE, LLC, an institutional investor affiliated with New Enterprise Associates, significantly reduced its stake in Gossamer Bio by selling 17.09 million shares for approximately $6.67 million. This substantial sale, representing nearly 7% of the company's market capitalization, occurred on February 23, 2026, the same day Gossamer Bio announced its Phase 3 PROSERA study for seralutinib in PAH missed its primary endpoint. The timing of this institutional selling, immediately after critical negative news, suggests a loss of confidence and could exert further downward pressure on the stock.
At the time of this filing, GOSS was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.1M. The 52-week trading range was $0.33 to $3.87. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.